Inovio Pharmaceuticals Inc.
INO
NGS
Sector: Healthcare
Industry: Biotechnology
2.37
USD
0.09
(3.95%)
Optionable: Yes Market Cap: 472 M 90-day average vol: 7,138,202
Previous close: 2.28 Open: 2.2 Bid: 2.44 Ask: 2.44
52 week range
1.38 9.96
Last updated: Monday 8th August 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Metrics
Valuation
Price per Sales TTM ($) | 354.79 |
Price per Book TTM ($) | 1.23 |
PE Ratio (TTM) | -1.20 |
Book Value per Share ($) | 2.16 |
5 Year PE Range | -3.8 , -2.8 |
Returns
7 Day Return | 24.08% | |
1 Month Return | 9.22% | |
3 Month Return | 0.00% | |
1 Year Return | -75.31% | |
3 Year Return | -6.69% | |
5 Year Return | -56.35% | |
YTD Return | -52.51% |
Risk
Custom Beta One Year | 1.86 |
Custom Beta Three Years | 0.29 |
Beneish M Score | -5.20 |
Altman Z Score | -1.90 |
Analyst Estimates
Financial Health
Technicals
RSI (14 Day) | 61.64 |
14 Day SMA ($) | 2.09 |
14 Day EMA ($) | 2.11 |
Money Flow Index | 58.69 |
Average True Range | 0.18 |
50 Day SMA ($) | 1.90 |
200 Day SMA ($) | 3.84 |
ADX | 24.70 |
MACD | 0.07 |
Growth
Free Cash Flow QoQ Growth | 60.59% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | -28.00% |
Revenue QoQ Growth | -76.28% |
EPS YoY Growth | 0.00% |
Profitability
Chart
News
Why Inovio Stock Tumbled on a Good Day for the Market Wednesday
Yahoo Finance 3/2/2022
Inovio adopts new strategy in pursuit of regulatory approval for experimental Covid-19 vaccine
Yahoo Finance 3/2/2022
Inovio COVID vaccine weaker vs Omicron in lab test; phase 3 trial enrollment paused
Seeking Alpha 3/2/2022
Inovio Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call Presentation
Seeking Alpha 3/2/2022
Inovio Pharmaceuticals (INO) Q4 2021 Earnings Call Transcript
Yahoo Finance 3/2/2022
Inovio Pharmaceuticals, Inc. (INO) CEO Dr. Joseph Kim on Q4 2021 Results - Earnings Call Transcript
Seeking Alpha 3/1/2022
Inovio Pharmaceuticals (INO) Reports Q4 Loss, Tops Revenue Estimates
Yahoo Finance 3/1/2022
Inovio Pharmaceuticals results miss on the bottom line; shares down 9%
Seeking Alpha 3/1/2022
UPDATE 2-Inovio lab tests show COVID vaccine weaker against Omicron, trial enrollment paused
Yahoo Finance 3/1/2022
Inovio Pharmaceuticals GAAP EPS of -$1.45 misses by $0.19, revenue of $1.77M beats by $0.31M
Seeking Alpha 3/1/2022
INOVIO Reports Fourth Quarter 2021 and Year-End Financial Results
Yahoo Finance 3/1/2022
2 Money-Burning Biotech Stocks to Avoid
Yahoo Finance 3/1/2022
Can Inovio Pharmaceuticals Q4 results bring earnings surprise?
Seeking Alpha 2/28/2022
Shareholders in Inovio Pharmaceuticals (NASDAQ:INO) have lost 78%, as stock drops 12% this past week
Yahoo Finance 2/17/2022
Alkermes (ALKS) Q4 Earnings and Revenues Beat Estimates
Yahoo Finance 2/16/2022
INOVIO to Report Fourth Quarter and Year-End 2021 Financial Results on March 1, 2022
Yahoo Finance 2/15/2022
Molina Healthcare (MOH) Q4 Earnings Beat on Higher Premiums
Yahoo Finance 2/10/2022
Humana (HUM) Q4 Earnings Beat Estimates on Membership Growth
Yahoo Finance 2/2/2022
Could Inovio Pharmaceuticals Become the Next Moderna?
Yahoo Finance 2/2/2022
Trend Analysis & Forecast
Read more on this trend analysis & forecast here - uptrenddowntrend.com
Trendlast: 46.037
Financials
INO Income Statement
Annual
| Dec-12 | Dec-13 | Dec-14 | Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 4 M | 13 M | 10 M | 41 M | 35 M | 42 M | 30 M | 4 M | 7 M | 2 M |
| Cost of sales | -2 M | -2 M | -2 M | -2 M | -3 M | -4 M | -5 M | -6 M | -5 M | -6 M |
| Gross operating profit | 660003 | 10 M | 8 M | 28 M | 8 M | 29 M | 30 M | 4 M | 7 M | 1 M |
| Selling Gen & administrative expense | 11 M | 14 M | 16 M | 18 M | 24 M | 28 M | 29 M | 27 M | 37 M | 54 M |
| Research & development expense | 18 M | 21 M | 34 M | 58 M | 89 M | 99 M | 95 M | 88 M | 94 M | 249 M |
| Operating income | -25 M | -22 M | -39 M | -35 M | -77 M | -85 M | -94 M | -111 M | -124 M | -301 M |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income net | 5 M | -45 M | 3 M | 4 M | 2 M | -5 M | -3 M | -4 M | -33 M | -3 M |
| Pre-tax Income (EBT) | -20 M | -66 M | -36 M | -31 M | -74 M | -88 M | -95 M | -121 M | -163 M | -303 M |
| Income taxes | 0 | 0 | 0 | -2 M | 0 | 0 | 2 M | -257335 | 0 | 0 |
| Net income from total operations | -20 M | -66 M | -36 M | -29 M | -74 M | -88 M | -97 M | -121 M | -167 M | -304 M |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total net income | -20 M | -66 M | -36 M | -29 M | -74 M | -88 M | -97 M | -119 M | -166 M | -304 M |
| Preferred dividends | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net income available for common | -20 M | -66 M | -36 M | -29 M | -74 M | -88 M | -97 M | -121 M | -167 M | -304 M |
| Depreciation | 2 M | 2 M | 2 M | 2 M | 3 M | 4 M | 5 M | 6 M | 5 M | 6 M |
| Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income before depreciation (EBITDA) | -23 M | -19 M | -38 M | -33 M | -74 M | -85 M | -90 M | -107 M | -150 M | -297 M |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic EPS total | -0.56 | -1.44 | -0.61 | -0.43 | -1.01 | -1.08 | -1.05 | -1.21 | -1.07 | -1.45 |
| Diluted EPS total | -0.56 | -1.44 | -0.64 | -0.44 | -1.01 | -1.09 | -1.05 | -1.21 | -1.07 | -1.45 |
Top MarketXLS Rank stocks
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started today
Stand with Ukraine
As the situation in Ukraine escalates, many of us in MarketXLS are left with emotions too overwhelming to name. If you’d like to show your support, but aren’t sure how to, we want to help make it easier for you to act.
For any amount donated, we’ll extend your MarketXLS subscription for double of the donated amount. Please send proof of your payment to support@marketxls.com to avail the extention
From all of us at MarketXLS, thank you!